The value of biochemical markers of bone turnover in osteoporosis

Journal of Rheumatology

Volumn 24, Issue 6, 1997, Pages 1215-1217

  Eastell, Richard ^a,b   Blumsohn, Aubrey ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alkaline phosphatase; Collagen; Hydroxyproline; Osteocalcin; Osteoporosis; Pyridinium crosslinks

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; HYDROXYPROLINE; OSTEOCALCIN; PYRIDINIUM DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; COLLAGEN; FEMALE; HUMANS; HYDROXYPROLINE; OSTEOCALCIN; OSTEOPOROSIS;

EID: 0030927286     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rodin A, Duncan A, Quartero HWP, et al: Serum concentration of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy. J Clin Endocrinol Metab 1989;68:1123-7.
2. Melkko J, Niemi S, Risteli L, et al: Radioimmunoassay of the carboxyterminal propeptide of human type 1 procollagen. Clin Chem 1990;36:1328-32.
3. Smedsrod B, Melkko J, Risteli L, et al: Circulating c-terminal propeptide of type 1 procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990;271:345-50.
4. Ristelli J, Niemi S, Kauppila S, et al: Collagen propeptides as indicators of collagen assembly. Acta Orthop Scand 1995;(suppl)66:1-6.
5. Price PA, Otsuka AS, Poser JW, et al: Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA 1976;13:1447-51.
6. Crofton PM: Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children - Age-dependent reference ranges and changes in liver and bone disease. Clin Chem 1992;38:663-70.
7. Behr W, Barnert J: Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: A simplified method and its clinical plausibility. Clin Chem 1986;32:1960-6.
8. Hill CS, Wolfert RL: The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clinica Chimica Acta 1989;186:315-20.
9. Colwell A, Russell RGG, Eastell R: Factors affecting the assay of 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993;23:341-9.
10. Segrest JP: Urinary metabolites of collagen. Methods Enzymol 1952;82:398-401.
11. Eyre DR, Koob TJ, Van Ness KP: Quantitation of hydroxypyridinium crosslinks in collagen by high performance liquid chromatography. Anal Biochem 1984;137:380-8.
12. Seyedin SM, Kung VT, Daniloff YN, et al: Immunoassay for urinary pyridinoline - The new marker of bone resorption. J Bone Miner Res 1993;8:635-41.
13. Hanson DA, Weis MAE, Bollen A, et al: A specific immunoassay for monitoring human bone resorption: Quantitation of type 1 collagen cross-linked n-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
14. Bonde M, Qvist P, Fledelius C, et al: Immunoassay for quantifying type 1 collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
15. Risteli J, Elomaa I, Niemi S, et al: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen - A new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
16. Lam KW, Lee P, Li CY, et al: Immunological and biochemical evidence for identity of tartrate-resistant isoenzymes of acid phosphatases from human serum and tissues. Clin Chem 1980;26;420-2.
17. Kadoya Y, Al-Saffar N, Kobayashi A, Revell PA: The expression of osteoclast markers on foreign body giant cells. Bone Miner 1994;27:85-96.
18. Delmas PD, Schlemmer A, Gineyts E, et al: Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991;6:639-44.
19. Eastell R, Robins SP, Colwell A, et al: Evaluation of bone turnover in type 1 osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis Int 1993;3:255-60.
20. Blumsohn A, Eastell R: Prediction of bone loss in postmenopausal women (commentary). Eur J Clin Invest 1992;22:764-6.
21. Christiansen C, Riis BJ, Rodbro P: Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporosis 1990;1:35.
22. Keen RW, Harris PA, Thompson PW, et al: Early postmenopausal bone loss and biochemical markers. J Bone Miner Res 1994;9:S399.
23. Hannon R, Blumsohn A, Colwell A, et al: Biochemical markers of bone turnover and the prediction of spinal bone loss in older women. J Bone Miner Res 1994;9:S399.
24. Dresner-Pollak R, Maitland LA, Krasnow M, et al: Can biochemical markers predict bone loss in elderly women? J Bone Miner Res 1994;9:S385.
25. Reeve J, Pearson J, Mitchell A, et al: Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. Calcif Tissue Int 1995;57:105-10.
26. Adami S, Passeri M, Ortolani S, et al: Effects of oral alendronate and intranasal calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
27. Civitelli R, Gonnelli S, Zacchei F, et al: Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 1988;82:1268-74.
28. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Invest 1994;79:1693-700.
29. Hall GM, Spector TM, Delmas PD: Markers of bone metabolism in postmenopausal women with rheumatoid arthritis: Effect of corticosteroids and hormone replacement therapy. Arthritis Rheum 1995;38:902-6.
30. Harris ST, Gertz BJ, Genant HK, et al: The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399-406.
31. Chesnut CH III, McClung MR, Ensrud EK, et al: Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
32. Rossini M, Gatti D, Zamberlan N, et al: Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994;9:1833-7.